Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides

Shots:

• Ionis has granted Sobi global exclusive rights of olezarsen excl. the US, Canada & China to treat familial chylomicronemia syndrome (FCS) & severely elevated triglycerides; Ionis to independently market Olezarsen in the US, whereas Theratechnologies holds the rights in Canada
• As per the deal, Ionis will get an upfront, with potential milestone payments & net sales-based tiered royalties while Sobi will handle future regulatory filings & marketing in its licensed regions
• Additionally, Olezarsen’s MAA is under EMA review & is being evaluated in 3 P-III trials for severe hypertriglyceridemia: ESSENCE (data expected by mid-2025), plus CORE & CORE2 (data of both anticipated in H2’25). 

Ref: Businesswire | Image: Ionis & Sobi

Related News:- Sobi Reports the US FDA’s sNDA Acceptance of Doptelet (Avatrombopag) to Treat Pediatric Immune Thrombocytopenia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com